Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Merrimack Pharmaceuticals...

    NASDAQ: MACK · Real-Time Price · USD
    15.14
    0.01 (0.07%)
    At close: May 17, 2024, 9:59 PM

    Merrimack Pharmaceuticals Statistics

    Share Statistics

    Merrimack Pharmaceuticals has 14.79M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 14.79M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 9.66M

    Failed to Deliver (FTD) Shares

    n/a
    		 278,235

    FTD / Avg. Volume

    n/a
    		 152.35%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -162.36 and the forward PE ratio is null. Merrimack Pharmaceuticals's PEG ratio is 6.52.

    PE Ratio

    n/a
    		 -162.36

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 10.23

    P/FCF Ratio

    n/a
    		 -125.99

    PEG Ratio

    n/a
    		 6.52
    Financial Ratio History

    Enterprise Valuation

    Merrimack Pharmaceuticals has an Enterprise Value (EV) of 185.76M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -85.37

    EV / EBIT

    n/a
    		 -122.05

    EV / FCF

    n/a
    		 -122.05

    Financial Position

    The company has a current ratio of 43.5, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 43.5

    Quick Ratio

    n/a
    		 43.5

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -6.3% and Return on Invested Capital is -11.73%.

    Return on Equity

    n/a
    		 -6.3%

    Return on Assets

    n/a
    		 -6.15%

    Return on Invested Capital

    n/a
    		 -11.73%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 n/a

    Employee Count

    n/a
    		 0

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 12K

    Effective Tax Rate

    n/a
    		 -1.03%

    Stock Price Statistics

    The stock price has increased by 2.92% in the last 52 weeks. The beta is 1.42, so Merrimack Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.42

    52-Week Price Change

    n/a
    		 2.92%

    50-Day Moving Average

    n/a
    		 14.86

    200-Day Moving Average

    n/a
    		 13.46

    Relative Strength Index (RSI)

    n/a
    		 78.97

    Average Volume (20 Days)

    n/a
    		 182,633

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -2.18M

    Net Income

    n/a
    		 -1.18M

    EBITDA

    n/a
    		 -2.18M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -0.08
    Full Income Statement

    Balance Sheet

    The company has 5.99M in cash and 0 in debt, giving a net cash position of 5.99M.

    Cash & Cash Equivalents

    n/a
    		 5.99M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -548.82M

    Total Assets

    n/a
    		 244.32M

    Working Capital

    n/a
    		 221.65M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -1.52M and capital expenditures 0, giving a free cash flow of -1.52M.

    Operating Cash Flow

    n/a
    		 -1.52M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -1.52M

    FCF Per Share

    n/a
    		 -0.11
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MACK does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -0.62%

    FCF Yield

    n/a
    		 -0.79%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for MACK.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 6, 2019. It was a forward split with a ratio of 1271:1000.

    Last Split Date

    n/a
    		 Sep 6, 2019

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 1271:1000

    Scores

    Altman Z-Score

    n/a
    		 4.99

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist